title: Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.
authors.forename: Tarek
authors.initials: T
authors.lastname: El-Sawy
authors.forename: Anita L
authors.initials: AL
authors.lastname: Sabichi
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Myers
authors.forename: Merrill S
authors.initials: MS
authors.lastname: Kies
authors.forename: William N
authors.initials: WN
authors.lastname: William
authors.forename: Bonnie S
authors.initials: BS
authors.lastname: Glisson
authors.forename: Scott
authors.initials: S
authors.lastname: Lippman
authors.forename: Bita
authors.initials: B
authors.lastname: Esmaeli
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D000068818:Cetuximab; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D008297:Male; D009918:Orbital Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D004815:Epidermal Growth Factor; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab